BTAI Overview
Upcoming Projects (BTAI)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BTAI)
-
Discussing the Phase 2 data on BioXcel's BXCL701 in metastatic SCNC-variant castration-resistant prostate cancer
Ticker: BTAI
Executed On: Mar 23, 2023 at 11:00 AM EDT -
Overview of Acute Agitation and the potential of dexmedetomidine film (BXCL501)
Ticker: BTAI
Executed On: Jul 26, 2022 at 01:00 PM EDT -
Discussing BioXcel’s BXCL501 for Agitation Associated with Schizophrenia and Bipolar Disorders, following PDUFA date extension by 3 months to April 5, 2022
Ticker: BTAI
Executed On: Mar 08, 2022 at 10:30 AM EST
Expired Projects (BTAI)
-
Examining BioXcel’s BXCL501 for the Treatment of Opioid Withdrawal Symptoms, with recent data to digest
Ticker: BTAI
Execute By: Jul 30, 2021 -
A Second Opinion: BXCL501 in Acute Agitation: Market Potential, Use Case Scenarios and Safety Profile with an ER doc
Ticker: BTAI
Execute By: Sep 25, 2020
Upcoming & Overdue Catalysts (BTAI)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BTAI)
-
BioXcel's (BTAI) BXCL501 in Opioid Withdrawal Symptoms Phase 1b/2 top-line data due 1Q 2021
Ticker: BTAI
Occurred on: Mar 31, 2021 -
BioXcel Therapeutics (BTAI) Announces BXCL501 Phase 1b data release in the Treatment of Agitation in Patients with Schizophrenia
Ticker: BTAI
Occurred on: Jul 22, 2019
Strategic Initiatives (BTAI)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
